Cite

HARVARD Citation

    Marchetti, C. et al. (2015). Advances in anti-angiogenic agents for ovarian cancer treatment: The role of trebananib (AMG 386). Critical reviews in oncology/hematology. 94 (3), pp. 302-310. [Online]. 
  
Back to record